Early de-intensification of antiplatelet therapy in high-bleeding-risk (HBR) patients is associated with lower bleeding and no ischemic penalty at 15 months, despite the allowance of routine care at 1 year, confirming the 12-month results of the MASTER DAPT trial, new findings show.